Literature DB >> 23634359

Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus study.

Omar Khan1, Aaron E Miller, Carlo Tornatore, J Theodore Phillips, Christopher J Barnes.   

Abstract

A modified Delphi process assessed current multiple sclerosis (MS) practice patterns for secondary and primary progressive MS (secondary progressive MS [SPMS] and primary progressive MS [PPMS]). In early 2011, 2 sequential, case-based surveys were administered to 75 US MS specialists to assess treatment practices and patient management. Respondents were from geographically diverse US academic (42%) and community (58%) treatment centers. There was consensus (≥75% agreement in responses) to switch disease-modifying therapies for a patient with SPMS with both MRI activity and disability progression (95%), but no consensus on treatment selection. For PPMS, responses supported diagnosis using spinal MRI (100%) and lumbar puncture (75%) and treatment initiation in patients with brain gadolinium-enhancing lesions with or without spinal cord lesions (85%); however, there was no consensus on treatment initiation with spinal cord lesions alone or initial therapy. The lack of agreement among US MS experts on the best treatment approaches for SPMS or PPMS highlights the need for effective therapies.

Entities:  

Year:  2012        PMID: 23634359      PMCID: PMC3613192          DOI: 10.1212/CPJ.0b013e31824cb0ac

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  19 in total

Review 1.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

Review 2.  Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review.

Authors:  Annette Langer-Gould; Rita A Popat; Stella M Huang; Kristin Cobb; Paulo Fontoura; Michael K Gould; Lorene M Nelson
Journal:  Arch Neurol       Date:  2006-12

Review 3.  A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.

Authors:  Shekoufeh Nikfar; Roja Rahimi; Mohammad Abdollahi
Journal:  Clin Ther       Date:  2010-10       Impact factor: 3.393

4.  MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability.

Authors:  D K B Li; U Held; J Petkau; M Daumer; F Barkhof; F Fazekas; J A Frank; L Kappos; D H Miller; J H Simon; J S Wolinsky; M Filippi
Journal:  Neurology       Date:  2006-05-09       Impact factor: 9.910

5.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

Review 6.  New approaches in the management of multiple sclerosis.

Authors:  Laurie J Barten; Douglas R Allington; Kendra A Procacci; Michael P Rivey
Journal:  Drug Des Devel Ther       Date:  2010-11-24       Impact factor: 4.162

Review 7.  Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D S Goodin; B A Cohen; P O'Connor; L Kappos; J C Stevens
Journal:  Neurology       Date:  2008-09-02       Impact factor: 9.910

8.  Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS.

Authors:  L Kappos; C Polman; C Pozzilli; A Thompson; K Beckmann; F Dahlke
Journal:  Neurology       Date:  2001-12-11       Impact factor: 9.910

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate.

Authors:  C Ford; A D Goodman; K Johnson; N Kachuck; J W Lindsey; R Lisak; C Luzzio; L Myers; H Panitch; J Preiningerova; A Pruitt; J Rose; H Rus; J Wolinsky
Journal:  Mult Scler       Date:  2010-01-27       Impact factor: 6.312

View more
  5 in total

1.  Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus study.

Authors:  Omar Khan
Journal:  Neurol Clin Pract       Date:  2012-12

2.  Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus study.

Authors:  William J Weiner
Journal:  Neurol Clin Pract       Date:  2012-12

3.  Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a: Obtaining Recommendations Using the Delphi Technique.

Authors:  June Halper; Diego Centonze; Scott D Newsome; DeRen Huang; Christopher Robertson; Xiaojun You; Guido Sabatella; Vladimir Evilevitch; Leslie Leahy
Journal:  Int J MS Care       Date:  2016 Jul-Aug

4.  Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?

Authors:  Sarah L Minden; R Philip Kinkel; Helene T Machado; Jonathan S Levin; Meredith B Rosenthal; Lisa I Iezzoni
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-02-20

5.  Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany.

Authors:  Sabrina Müller; Tobias Heidler; Andreas Fuchs; Andreas Pfaff; Kathrin Ernst; Gunter Ladinek; Thomas Wilke
Journal:  Neurol Ther       Date:  2019-12-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.